- Association of Non‐Cytochrome P450 3A4‐Metabolized Statins Versus Atorvastatin With Major Adverse Cardiovascular Events in Patients With Cancer Receiving Tyrosine Kinase Inhibitors: A Propensity Score–Matched Target Trial Emulation
Journal of the American Heart Association · 2026
- Statins and non-cardiac surgery: continuation, not initiation
European Journal of Preventive Cardiology · 2026
- Impact of Evolocumab on LDL‐Cholesterol and Cardiovascular Outcomes in Patients With Established CVD: Systematic Review and Meta‐Analysis
Endocrinology Diabetes & Metabolism · 2026
- The effect of anti‐seizure medications on exposure to statins: A systematic review and meta‐analysis
Epileptic Disorders · 2026
- Cardiovascular outcomes of triglyceride-targeting lipid-lowering therapies in patients with CKD.
Kidney International Reports · 2026
- Severe Rhabdomyolysis With Minimal Muscular Symptoms After Long-Term Rosuvastatin Use: A Case Report and Brief Literature Review
Cureus · 2026
- Pharmacokinetic Evidence of an Abiraterone–Rosuvastatin Drug Interaction Resulting in Rhabdomyolysis and Acute Kidney Injury
Journal of clinical lipidology · 2026
- Effects of evolocumab on lipid profile and circulating endothelial biomarkers in patients undergoing primary percutaneous coronary intervention
Science Progress · 2026
- Proprotein Convertase Subtilisin/Kexin Type 9: From Biology to Therapeutic Targeting in Cardiovascular Disease
European Journal of Clinical Investigation · 2026
- Clinical efficacy of ezetimibe add-on to atorvastatin on lipid profile in post-PCI patients: evidence from a south indian population
BMC Cardiovascular Disorders · 2026
- The association between atorvastatin use and prothrombin time, apolipoprotein A-I levels, and apolipoprotein B levels in patients with type 2 diabetes mellitus and no history of atherosclerotic cardiovascular diseases: a cross-sectional study
Postgraduate Medicine · 2026
- Atorvastatin improves hyperlipidemia-induced erectile dysfunction via PKA-associated eNOS phosphorylation at the Ser633 site
Sexual Medicine · 2026
- Deciphering the Mechanisms of Statin–Ezetimibe Drug Combinations Using Boolean Logical Modeling and Transcriptomic Data
CPT Pharmacometrics & Systems Pharmacology · 2026
- Aptamer targeting proprotein convertase subtilisin/kexin type 9: in vivo efficacy in a hypercholesterolemic rat model
Research in Pharmaceutical Sciences · 2026
- Impact of distinct bioactivation routes of clopidogrel ester analog vicagrel on CYP3A4-mediated interaction with atorvastatin in the intestine
European Journal of Pharmaceutical Sciences · 2026
- Clinical Outcomes of an ApoE Genotype-Guided Lipid-Lowering Strategy in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
Pharmacogenomics and Personalized Medicine · 2026
- Dose-stratified lipid-lowering efficacy and safety of oral PCSK9 inhibitors: a systematic review and meta-analysis
Journal of Cardiovascular Medicine · 2026
- Uncovering dysbetalipoproteinemia in a patient initially diagnosed with familial hypercholesterolemia: The role of whole exome sequencing and longitudinal follow-up in diagnostic precision and care
Journal of clinical lipidology · 2026
- LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction
JAMA · 2026
- LDL-C target attainment and treatment costs in high-risk and very-high-risk patients with or without bempedoic acid: A Spanish cohort simulation
PLoS ONE · 2026
- Enlicitide: The first oral PCSK9 inhibitor approved for treatment of hypercholesterolemia
Drug Discoveries & Therapeutics · 2026
- Effect of in-hospital initiation of alirocumab on clinical outcomes in Chinese ACS patients: findings from the Chinese Cardiovascular Association (CCA) Database-Chest Pain Center
Atherosclerosis · 2026
- Bleeding Risk Associated with Novel Oral Anticoagulants in Critically Ill Patients: A Scoping Review
Journal of Visualized Experiments · 2026
- Delayed-Onset Severe Statin-Induced Rhabdomyolysis Due to Atorvastatin-Ticagrelor Interaction in a Patient With Acute Coronary Syndrome: A Case Report
Cureus · 2026
- Right atrial appendage thrombosis after percutaneous left atrial appendage occlusion: a case report
Frontiers in Cardiovascular Medicine · 2026
- Standard- Versus Reduced-Dose Apixaban and Vitamin K Antagonists in Patients with Atrial Fibrillation and Advanced Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis
Journal of Clinical Medicine · 2026
- Atorvastatin Enhances Doxorubicin Efficacy in Breast Cancer Through Convergent Disruption of Drug Efflux, Heat-Shock Response, and DNA Hypermethylation
Current Pharmaceutical Design · 2026
- Sweroside attenuates heart failure with preserved ejection fraction via targeting PCSK9-CD36 interaction to reduce cardiac-hepatic lipotoxicity
Phytomedicine · 2026
- Complete Resolution of Pacemaker Lead Thrombus with Warfarin Following Direct Oral Anticoagulant Failure: A Case Report
2026
- Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in a Belgian healthcare setting
Journal of Medical Economics · 2026
- Convalescent Spontaneous Coronary Artery Dissection With Elevated Pericoronary Fat Attenuation Index
JACC Case Reports · 2026
- A Review of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Direct Oral Anticoagulants in Patients Undergoing Bariatric Surgery
Research and Practice in Thrombosis and Haemostasis · 2026
- A comprehensive study using multiple experimental models validated the potential blood pressure reduction effect of rivaroxaban
Current Molecular Pharmacology · 2026
- Distribution of apixaban plasma concentrations across prescribed dose groups for ischemic stroke prevention in atrial fibrillation
EP Europace · 2026
- Association of diabetes mellitus status and clinical outcomes of edoxaban in patients with atrial fibrillation: a sub-analysis from the ETNA-AF Asian registry
EP Europace · 2026
- Cause of death and competing risk in patients with device-detected atrial fibrillation treated with apixaban or aspirin: Insights from the ARTESiA trial
EP Europace · 2026
- Sex-specific effects of apixaban versus aspirin in subclinical atrial fibrillation: insights from the ARTESiA trial
EP Europace · 2026
- Association of body mass index with arrhythmia progression and outcomes in patients with subclinical atrial fibrillation: insights from the ARTESiA trial
EP Europace · 2026
- Real-world off-label apixaban dosing and clinical outcomes in patients with heart failure and end-stage kidney disease
Medicine · 2026
- Saddle pulmonary embolism detected by transthoracic echocardiography—a case report
Wiener klinische Wochenschrift · 2026
- Validation of an HPLC‐UV for Apixaban Stability‐Indicating Study
Biomedical Chromatography · 2026
- The role of ginkgo leaf extract and dipyridamole adjuvant treatment for reduction of lower limb deep vein thrombosis after proximal femoral nail antirotation surgery in elderly patients with intertrochanteric femoral fracture
Frontiers in Pharmacology · 2026
- Perioperative Glycemic Control and Outcomes in Cardiac Surgery: A Retrospective Cohort Study.
2026
- Early-Onset Amiodarone Pulmonary Toxicity at a Standard Maintenance Dose Masquerading as Decompensated Heart Failure: A Case Report and Literature Review
Cureus · 2026
- Development and Clinical Application of a Real-World Population Pharmacokinetic Model of Rivaroxaban in Asian Patients with Atrial Fibrillation
Clinical Pharmacokinetics · 2026
- SYSTEMATIC REVIEW OF VALIDATED METHODS FOR THE CO-ANALYSIS OF AMLODIPINE AND ATORVASTATIN
2026
- Extended Rivaroxaban Therapy for Cancer-Associated Low-Risk Pulmonary Embolism by Chemotherapy Status: Insights from the ONCO PE Trial
Thrombosis and Haemostasis · 2026
- Association of Edoxaban Pharmacokinetics With Bleeding in Older Patients With Atrial Fibrillation Treated With Low‐Dose Edoxaban: A Post Hoc Analysis of a Randomized Controlled Trial
Journal of the American Heart Association · 2026
- The application of low-dose rivaroxaban in elderly patients with atrial fibrillation
Frontiers in Pharmacology · 2026
- Astragaloside IV Reduces Sorafenib-Induced Cardiotoxicity by Inhibiting Apoptosis Through the STAT3/HIF-1α/Bcl-2 Signaling Pathway
International Journal of Molecular Sciences · 2026